GoldenGolden
Advanced Search
TLV Partners

TLV Partners

A venture capital firm in Israel that focuses on software enterprise, cybersecurity, mobile, marketing, internet of things and analytics sectors.

TLV Partners is a venture capital firm in Israel that focuses on software enterprise, cybersecurity, mobile, marketing, internet of things and analytics sectors. Founded 2015 in Tel Aviv, Israel by Eitan Bek and Rona Segev-Gal, it invests in early stage ventures. Its portfolio companies include Datree, Bond - The Post Purchase Company, Hunterz, Flip Fit, Next Insurance and ScyllaDB. As of February 2020, TLV Partners has made 34 investments. Their most recent investment was on February 6, 2020, when Datree raised $8M. TLV Partners has had one exit, which was PureSec. TLV Partners has raised three funds, their latest being TLV Partners Fund III. This fund was announced on February 9, 2020 and raised a total of $210M.

Timeline

2015
Founded

People

Name
Role
LinkedIn

Ronit Dulberg

CFO

Brian Sack

Analyst

Eitan Bek

Co-Founder & Managing Partner

Maya Goren Bar

Director of Marketing

Rona Segev-Gal

Co-Founder & Managing Partner

Shahar Tzafrir

Managing Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Aidoc

Bond - The Post Purchase Company

DataGen Technologies

Datree

Flip Fit

Hunterz

Next Insurance

Rookout

ScyllaDB

Stoke World

News

Title
Author
Date
Publisher
Description
Christine Hall
February 11, 2021
Crunchbase News
Immunai is leveraging single-cell technologies and machine-learning algorithms to map out millions of immune cells and their functions.
May 14, 2020
WebWire
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed funding, which will be used to further the development of its technology and business functi...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.